XIMEPEG (macrogol 4 000 + electrolytes + simeticone)
Reason for request
High clinical benefit in colonic lavage, though no demonstrated clinical advantage over other available preparations.
XIMEPEG has been granted marketing authorisation for intestinal lavage prior to an examination requiring a clean intestine, such as endoscopic or radiological exploration.
Its administration requires drinking 2 litres of water. After examination, patients should be encouraged to drink a large volume of liquid (at least 1 L) to compensate for the liquid loss incurred during preparation.
Its equivalence in terms of success of XIMEPEG colonic preparation compared to other relevant comparators (macrogol and electrolyte-based solution and MOVIPREP) has been established by two studies.
No data are available to support an improvement in quality-of-life nor an impact of colonic lavage, for example on the number of neoplastic lesions detected, relative to the comparators.
Clinical Benefit
Substantial |
- |
Clinical Added Value
no clinical added value |
- |
Therapeutic use
- |